Karyopharm Therapeutics | KPTI - 销售收入



金融业
股票价格
USD
资产
USD 131.42M
现金及等价物
USD 90.85M
销售成本
USD 1.35M
流动资产
USD 126.33M
流动负债
USD 117.3M
债务
USD 299.23M
股息收益率
0
EBIT
USD -26.76M
EBITDA
USD -26.2M
员工
325
EPS每股收益
USD -1.02
股本和储备
USD -265.65M
销售毛利
USD 33.72M
债务利息支出
USD 12.55M
利息收入
USD -0.15
贷款资金
USD 264.49M
市值
USD 210.6M
净收入
USD -22.39M
营业费用
USD 61.83M
营业利润
USD -26.76M
普通股股本
USD 22.54M
税前利润
USD -22.39M
销售收入
USD 35.07M
销售和管理费用
USD 10.42M
股票
USD 4.04M
贸易债权人
USD 4.28M
应收帐款人
USD 23.36M


销售 更改 日
AbbVie USD 16.99B 1.99B 2026-06
Abbott USD 12.59B 1.43B 2026-06
Amgen USD 10.1B 1.48B 2026-06
AstraZeneca USD 15.38B 90M 2026-06
BioCryst Pharmaceuticals USD 218.25M 188.3M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Eli Lilly USD 22.97B 3.17B 2026-06
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
GlaxoSmithKline GBP 8.41B 781M 2026-06
Incyte USD 1.67B 400M 2026-06
J&J USD 25.31B 1.21B 2026-06
Karyopharm Therapeutics USD 35.07M 987K 2026-03
MacroGenics USD 20.8M 20.43M 2026-03
Merck USD 16.6B 310M 2026-06
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Novartis USD 14.41B 1.3B 2026-06
Novartis USD 13.11B 750M 2026-03
Pfizer USD 15.03B 530M 2026-06
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Roche Holding CHF 30.36B 14.71B 2026-06
Sangamo BioSciences USD 356K 125K 2024-06
Takeda JPY 1.22T 130B 2026-06
Tectonic Therapeutic USD 0 0 2024-12
TG Therapeutics USD 240.34M 45.54M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Xencor USD 51.22M 46.71M 2026-06